Research Grade Vesencumab (DHA30101)

Catalog No.

DHA30101

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

NRP1, Neuropilin-1, VEGF165R, NRP, CD304, Vascular endothelial cell growth factor 165 receptor

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O14786

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MNRP1685A, CAS: 1205533-60-3

Clone ID

Vesencumab

Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans, PMID: 22707361

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors, PMID: 24604265

Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice, PMID: 22074316

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors, PMID: 24633809

Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors, PMID: 22962439

Document Download

Research Grade Vesencumab.pdf